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Group performance status, mini-mental state examination, 
body mass index, Cumulative Illness Rating Scale, number 
of drugs and the presence of caregiver. Cancer sites (breast 
46.5 %, colorectal 21.3 %, lung 6.4 %, prostate 5.5 %, uri-
nary tract 5.0 %, other 15.3 %) and cancer stages (I 37 %, II 
22 %, III 19 %, IV 22 %) were also included in the model. 
All-cause mortality was recorded. Three grades of severity 
of the Onco-MPI score (low risk: 0.0–0.46, medium risk: 
0.47–0.63, high risk: 0.64–1.0) were calculated using REC-
PAM method. Discriminatory power and calibration were 
assessed by estimating survival C-indices, along with 95 % 
confidence interval (CI) and the survival-based Hosmer–
Lemeshow (HL) measures.
Results One-year mortality incidence rate was 17.4 %. 
A significant difference in mortality rates was observed in 
Onco-MPI low risk compared to medium- and high-risk 
patients (2.1 vs. 17.7 vs. 80.8 %, p < 0.0001). The discrimi-
natory power of one-year mortality prediction of the Onco-
MPI was very good (survival C-index 0.87, 95 % CI 0.84–
0.90) with an excellent calibration (HL p value 0.854).
Conclusion Onco-MPI appears to be a highly accurate 
and well-calibrated predictive tool for one-year mortality in 
older cancer patients that can be useful for clinical decision 
making in this age group.
Keywords Cancer · Elderly · Prognosis · Mortality · 
Multidimensional prognostic index (MPI) · Comprehensive 
geriatric assessment (CGA)
Introduction
In both Europe and in the USA, the majority of persons 
who receive a cancer diagnosis are aged 65 years or older 
(Siegel et al. 2012), and the number of older patients with 
Abstract 
Purpose A multidimensional prognostic index (MPI) 
based on a comprehensive geriatric assessment (CGA) has 
been developed and validated in independent cohorts of 
older patients demonstrating good accuracy in predicting 
one-year mortality. The aim of this study was to develop 
a cancer-specific modified MPI (Onco-MPI) for mortality 
prediction in older cancer patients.
Methods We enrolled 658 new cancer subjects ≥70 years 
(mean age 77.1 years, 433 females, 65.8 %) attending 
oncological outpatient services from September 2004 to 
June 2011. The Onco-MPI was calculated according to a 
validated algorithm as a weighted linear combination of the 
following CGA domains: age, sex, basal and instrumental 
activities of daily living, Eastern Cooperative Oncology 
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cancer is expected to rise substantially in the next decades 
(Smith et al. 2009). One of the priorities for both clinicians 
and researchers is the assessment, treatment planning and 
evaluation of outcomes of these subjects. However, ongo-
ing enrollment biases with underrepresentation of older 
individuals in clinical trials of cancer (Talarico et al. 2004; 
Scher and Hurria 2012) greatly limit that evidence-based 
clinical decisions be taken in such a population. Particu-
larly, determining life expectancy related to functional 
status and comorbidity seems to be of utmost importance 
in that it could help in moving beyond arbitrary age-based 
cutoffs when making decisions of treating older patients 
with chemotherapy both in the adjuvant setting and for 
advanced disease (Gill 2012). Several studies demon-
strated that in older subjects, the final prognosis is linked 
to multimorbidity and multidimensional impairment, i.e., 
an impairment in the functional, cognitive, nutritional 
and psychosocial domains (Yourman et al. 2012), that are 
appropriately explored at their best by using a comprehen-
sive geriatric assessment (CGA) also in older patients with 
cancer (Caillet et al. 2014). Indeed, while recent guidelines 
recommend life expectancy inclusion in clinical decision-
making paths in older age (Pilotto et al. 2015), at present, 
no validated CGA-based prognostic instruments are avail-
able to guide treatment plan in older cancer patients (Baijal 
and Periyakoil 2014).
Recently, a multidimensional prognostic index (MPI) 
has been developed and validated on the basis of a stand-
ardized CGA (Pilotto et al. 2008), which take into account 
eight domains related to functional and cognitive status, 
nutrition, comorbidities, pressure sore risk, number of 
medications and social status. The MPI has been shown 
to be an accurate predictor for short- and long-term mor-
tality in patients hospitalized for acute or reactivation of 
chronic diseases such as community-acquired pneumonia, 
dementia, congestive heart failure, chronic kidney disease, 
and other most common disorders leading to death in the 
elderly (Pilotto et al. 2012a, b, c) as well as in hospitalized 
patients with cancer (Giantin et al. 2013). The aim of this 
study was to develop a cancer-specific MPI (Onco-MPI) 
applicable in the outpatient setting to predict mortality in 
older patients with different types of cancer, so recognizing 
heterogeneity in this age group and leading to individual-
ized approaches toward cancer treatment.
Methods
Study population
Patients aged ≥70 referred to the Geriatric Oncology Pro-
gram of the Istituto Oncologico Veneto (IOV) in Padova, 
Italy, from September 2004 to June 2011 were included. 
Patients needed to have a confirmed diagnosis of cancer 
and a complete CGA recorded in the clinical chart to be 
included. For all patients, the following variables were col-
lected: age, gender, Eastern Cooperative Oncology Group 
(ECOG) performance status (Oken et al. 1982), associated 
diseases and their severity graded according to Cumula-
tive Illness Rating Scale (CIRS) (Linn et al. 1968), present 
medications, the presence of pain, body mass index (BMI), 
site and stage of primary cancer, cancer treatment planned 
and/or received, living status/the presence of caregiver, 
basal and instrumental activities of daily living (ADL, 
IADL) (Katz et al. 1970; Lawton and Brody. 1969), mini-
mental state examination (MMSE) (Folstein et al. 1975) 
and the 15-item Geriatric Depression Scale (GDS) (Satin 
et al. 2009).
All patients were followed up with clinical visits every 
3–6 months with a median follow-up time of 2.5 years 
and a range of 0.0–8.2 years. For patients who died during 
the follow-up, the date of death was obtained from clini-
cal charts when available, and it was collected either from 
death certificates or by contacting demographic offices 
when not available. For subjects who did not experience the 
end point, survival time was censored at the time of the last 
available follow-up visit.
The oncological‑multidimensional prognostic index 
(Onco‑MPI)
To build the Onco-MPI, a weighted sum of the follow-
ing domains was computed (raw formula): age, sex, ADL, 
IADL, ECOG performance status, MMSE, BMI, CIRS, 
number of drugs, the presence of caregiver, cancer sites 
and cancer stages. Weights were estimated from a multi-
variable Cox proportional hazard model, within 1 year of 
follow-up. Each weighted sum was then normalized into a 
range that varies from 0 (lowest risk) to 1 (highest risk), 
subtracting the observed raw minimum value (i.e., −2.371) 
and then dividing such difference by the observed range 
(minimum to maximum span, i.e., 8.034). Three grades 
of Onco-MPI severity were estimated using RECursive 
Partition and AMalgamation (RECPAM) algorithm. At 
each partitioning step, the method chooses the best binary 
split (cutoff) to maximize the difference in the outcome of 
interest. Discriminatory power was assessed by estimat-
ing survival C-indices, along with 95 % confidence inter-
val (CI) (Pencina and D’Agostino 2004), and the survival-
based Hosmer–Lemeshow (HL) measure of calibration 
(D’Agostino and Nam 2004) was also assessed.
Statistical analysis
Patients’ baseline characteristics were reported as 
mean ± standard deviation (SD) or frequencies and 
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percentage for continuous and categorical variables, 
respectively. Medians and ranges were reported for con-
tinuous variables. The overall survival was defined as the 
time between date of first visit and death. Mortality inci-
dence rates were reported as the observed number of events 
for 100 person-years and were compared using a Poisson 
model. Time-to-death analyses were performed using uni-
variate and multivariate Cox regression models, within 
1 year of follow-up, and results were expressed as hazard 
ratios (HRs) and 95 % CI. Survival curves were reported 
according to the Kaplan–Meier method.
All statistical analyses were performed using SAS ver-
sion 9.3 (SAS Institute, Cary, NC).
Results
Of all older patients ≥70 years referred for evaluation as 
new patients to the Geriatric Oncology Program from 
September 2004 to June 2011, full CGA data were avail-
able for 658 patients. Baseline patients’ characteristics are 
shown in Table 1.
After a median follow-up time of 2.5 years (range 0.0–
8.2), 105 patients died, with an overall one-year mortality 
incidence rate of 17.4 %. Univariate Cox regressions analy-
sis showed that 11 domains of the CGA were significantly 
associated with mortality (Table 2).
In detail, one-year mortality risk was associated with 
increasing age, male sex, lower MMSE, impaired ADL, 
impaired IADL, number of severe comorbidities accord-
ing to CIRS, poor ECOG performance status, the presence 
of caregiver and late-stage cancer, whereas having a breast 
cancer diagnosis (vs. all other cancers) and higher BMI 
predicted lower mortality.
As shown in Table 3, the weights used to build the Onco-
MPI were the regression coefficients (logarithm of the HR) 
estimated from a multivariate Cox model (Table 4). After 
the normalization procedure, our score ranged from 0 (low 
risk) to 1 (high risk).
The Onco-MPI score had a good discriminatory power, 
yielding a C-statistic of 0.869 (95 % CI 0.841–0.897) and a 
good calibration measure (HL p value = 0.854). Three risk 
score categories were estimated for Onco-MPI score using 
RECPAM method, according to the following cutoffs: 
0–0.46 (low risk), 0.47–0.63 (moderate risk) and 0.64–1 
(high risk). A significant difference in mortality rates was 
observed for Onco-MPI low risk compared to medium- and 
high-risk patients (2.1 vs. 17.7 vs. 80.8 %, respectively, 
p < 0.001). Kaplan–Meier survival curves for one-year 
mortality risk, according to the three risk score categories 
(low risk, medium risk and high risk), are shown in Fig. 1.
Discussion
In the present study, the cancer-specific Onco-MPI 
appeared to be a highly accurate and well-calibrated prog-
nostic tool for one-year mortality in older cancer patients 
that can be useful for defining homogeneous prognostic 
categories and clinical decision making in this age group. 
Indeed, therapeutic decisions in elderly cancer patients are 
not fully informed unless heterogeneity of the aging process 
is taken into account. Actually, some forms of CGA have 
been successfully used to establish individualized treatment 
plans of treatment (Caillet et al. 2011) and in defining risk 
of toxicity from treatments in older cancer patients (Hurria 
et al. 2011; Extermann et al. 2012). Thus, current clinical 
guidelines for cancer in older age recommend to implement 
the CGA methodology (Extermann et al. 2005; Biganzoli 
et al. 2012; Droz et al. 2010; Pallis et al. 2010) in order to 
determine the residual biological, psychological and func-
tional capabilities of the older patients, i.e., the grade of 
frailty (Baijal and Periyakoil 2014; Hamaker et al. 2012), 
for developing a personalized plan for treatments and inter-
ventions. Indeed, whatever the definition and methodology 
used to evaluate frailty, frail patients have a higher mor-
tality compared to non-frail patients. In a previous study, 
we showed that frail hospitalized patients, being treated 
despite poor conditions, had poor outcome (Basso et al. 
2008). Furthermore, frail lymphoma patients had same 
outcome whether they were treated with active modified 
oncological treatment or palliative care (Tucci et al. 2009). 
The prognostic evaluation of life expectancy emerges thus 
as a key factor by which pros and cons of active oncologi-
cal treatment must be weighted, both in the adjuvant setting 
and in the metastatic setting. Prognosis could be also fun-
damental for balancing the harm–benefit and cost–benefit 
ratios in situations of uncertainty when prescribing high-
cost drugs or treatments requiring multiple admissions with 
potential impact on quality of life. In recent years, some 
prognostic scores have been proposed, but none of these 
was based on information collected by a standardized CGA 
(Yourman et al. 2012; Pilotto et al. 2015; Baijal and Peri-
yakoil 2014). The MPI has been previously validated in 
older hospitalized patients suffering from major diseases, 
including several types of cancer (Pilotto et al. 2012a, b, 
c; Giantin et al. 2013), with a significant higher predic-
tive power than other widely used frailty indexes (Bellera 
et al. 2012). In this cohort from an outpatient setting, we 
developed a modified MPI that included, compared to the 
originally MPI, the ECOG performance status (instead of 
the Exton-Smith scale), the MMSE (instead of the Short 
Portable Mental Status Questionnaire, SPMSQ) and the 
BMI (instead of the Mini Nutritional Assessment, MNA) 
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Table 1  Baseline patients’ 
characteristics
BMI body mass index, ADL activities of daily living, IADL instrumental activities of daily living, CIRS 
Cumulative Illness Rating Scale, MMSE mini-mental state examination, ECOG Eastern Cooperative 
Oncology Group
Variable Category
No of patients 658
Age (years) Mean ± SD 77.16 ± 5.11
Median (min–max) 77.00 (70.00–96.00)
Sex (n, %) Females 433 (65.81 %)
Males 225 (34.19 %)
BMI (kg/m2) Mean ± SD 25.49 ± 4.21
Median (min–max) 25.22 (15.50–47.56)
ADL Mean ± SD 5.71 ± 0.85
Median (min–max) 6.00 (0.00–6.00)
IADL Mean ± SD 6.83 ± 1.80
Median (min–max) 8.00 (0.00–8.00)
The presence of comorbidity (n, %) No 495 (75.23 %)
Yes 163 (24.77 %)
Comorbidity index CIRS Mean ± SD 1.71 ± 1.29
Median (min–max) 2.00 (0.00–7.00)
No of total comorbidities CIRS Mean ± SD 2.72 ± 1.60
Median (min–max) 3.00 (0.00–9.00)
No of severe comorbidities CIRS Mean ± SD 0.31 ± 0.60
Median (min–max) 0.00 (0.00–4.00)
MMSE (n, %) <24 119 (18.09 %)
≥24 539 (81.91 %)
The presence of psychiatric disease (n, %) No 606 (92.10 %)
Yes 52 (7.90 %)
Cancer stage (n, %) I 246 (36.39 %)
II 144 (21.88 %)
III 121 (18.39 %)
IV 147 (22.34 %)
Cancer treatment (n, %) No 160 (24.32 %)
Yes 498 (75.68 %)
No of drugs Mean ± SD 3.32 ± 2.43
Median (min–max) 3.00 (0.00–13.00)
ECOG performance status Mean ± SD 0.52 ± 0.72
Median (min–max) 0.00 (0.00–4.00)
Caregiver (n, %) No 193 (29.33 %)
Yes 465 (70.67 %)
15-item Geriatric Depression Scale (n, %) ≤ 5 497 (75.53 %)
> 5 161 (24.47 %)
Geriatric syndromes (n, %) No 609 (92.55 %)
Yes 49 (7.45 %)
Tumor site (n, %) Breast 306 (46.50 %)
Colorectal 140 (21.28 %)
Lung 42 (6.38 %)
Prostate 36 (5.47 %)
Other genitourinary 33 (5.02 %)
Other 101 (15.35 %)
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to evaluate functional, cognitive and nutritional status, 
respectively.
Notably, we further included in the prognostic model 
both patients’ cancer site and cancer stage variables, along 
with the main MPI domains, due to their clinical relevance 
on the mortality risk prediction. For tumor sites, some 
biases can have been introduced since breast cancer was 
the prevalent type (46.5 %) with early stages of disease 
being more represented for this tumor site, whereas other 
tumor sites, i.e., lung cancer, were far less prevalent, with 
higher stages of disease at first access. Globally, 75 % of 
patients received active oncology treatment whose impact 
on survival was not significant. Therefore, considering mul-
tidimensional aggregate information may go beyond the 
heterogeneity of the sample related to diverse cancer sites 
and stages, and the variety of treatments used (endocrine 
agents, several types of chemotherapy regimens).
While screening tools based on abbreviated CGA 
showed high sensitivity with low specificity in predicting 
mortality (Smets et al. 2014; Bellera et al. 2012), CGA-
based prognostic scores similar to the Onco-MPI in older 
cancer patients have been poorly investigated. Recently, 
a study conducted on 249 older Asian cancer patients by 
using CGA items to build a prognostic nomogram based on 
six clinical laboratory items demonstrated a relatively low 
predictive accuracy for one-, two- and three-year overall 
survival with a C-index value of 0.71 (Kanesvaran et al. 
2011). The Onco-MPI was developed on more than 600 
patients using some CGA-based items which can be eas-
ily implemented in routine oncological practice to drive 
treatment decisions. A time horizon of 1 year was chosen 
because we focused on a short-term mortality risk predic-
tion, which is particularly helpful to give systemic oncolog-
ical treatment or not in many cancers of the older people.
Table 2  Results from univariable Cox regressions for mortality risk prediction, within 1 year of follow-up in older cancer patients
BMI body mass index, ADL activities of daily living, IADL instrumental activities of daily living, CIRS Cumulative Illness Rating Scale, MMSE 
mini-mental state examination, ECOG Eastern Cooperative Oncology Group, Cont. Var. continuous variable
Variable Category HR (95 % CI) p value
Age Cont. Var. 1.076 (1.039–1.114) <0.001
Sex Male versus female 2.084 (1.422–3.056) <0.001
BMI Cont. Var. 0.870 (0.824–0.918) <0.001
ADL Cont. Var. 0.667 (0.582–0.764) <0.001
IADL Cont. Var. 0.765 (0.709–0.825) <0.001
The presence of comorbidity Yes versus no 1.420 (0.941–2.145) 0.095
Comorbidity Index CIRS Cont. Var. 1.011 (0.873–1.173) 0.880
No of total comorbidites CIRS Cont. Var. 1.036 (0.921–1.164) 0.557
No of severe comorbidites CIRS Cont. Var. 1.288 (0.985–1.685) 0.065
MMSE <24 versus ≥24 1.913 (1.253–2.922) 0.003
Psychiatric diseases Yes versus no 0.809 (0.376–1.742) 0.589
Cancer stage IV versus I 17.089 (8.189–35.659) <0.001
III versus I 4.555 (1.966–10.555) <0.001
II versus I 3.614 (1.546–8.443) 0.003
Cancer treatment Yes versus no 0.726 (0.478–1.105) 0.135
No of drugs Cont. Var. 1.036 (0.960–1.117) 0.363
Performance status (continuous) Cont. Var. 2.133 (1.766–2.576) <0.001
ECOG performance status (categorical) ≥3 versus 0 6.184 (2.163–17.679) <0.001
2 versus 0 7.418 (4.223–13.031) <0.001
1 versus 0 4.232 (2.658–6.738) <0.001
Caregiver Yes versus no 1.603 (1.002–2.565) 0.049
15-item Geriatric Depression Scale >5 versus ≤5 1.402 (0.926–2.125) 0.111
Syndromes Yes versus no 1.329 (0.693–2.550) 0.392
Tumor site Breast versus other 0.078 (0.038–0.157) <0.001
Colorectal versus other 0.401 (0.234–0.685) <0.001
Lung versus other 1.429 (0.815–2.506) 0.213
Prostate versus other 0.335 (0.131–0.856) 0.022
Other genitourinary versus other 1.372 (0.747–2.520) 0.308
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In this study, ECOG performance status was signifi-
cantly associated with mortality, thus confirming the well-
known prognostic role of this tool in oncology. Moreover, 
both ADL and IADL in our model were significantly asso-
ciated with mortality in univariable analysis, and the loss 
of significance in the multivariable analysis probably was 
related to interaction with other considered domains (Exter-
mann et al. 1998). The presence and number of severe 
comorbidities have also been found to be related to poor 
prognosis in the present study. Indeed, comorbidity has 
been consistently proven to be associated with worse sur-
vival in older cancer patients (Piccirillo et al. 2004). This 
has been shown to be independent of ECOG performance 
status (Firat et al. 2002) and functional status (Extermann 
et al. 1998). Weight loss or a low BMI was associated by 
reverse epidemiology with an increased risk of mortality 
in older age (Landi et al. 2000), a finding confirmed also 
in our cohort of cancer patients Furthermore, cognitive sta-
tus showed a strong prognostic value in our older cancer 
patients, confirming earlier findings suggesting dementia 
as an independent prognostic factor for survival in older 
subjects (Wolfson et al. 2001). Depression has been also 
proposed as a predictive factor of mortality in older can-
cer patients with controversial findings (Satin et al. 2009). 
In our study, the presence of depression was not associated 
with survival, and therefore it was not considered among 
variables for building the Onco-MPI. In both the geriatric 
and oncology literature, social isolation has been linked 
to an increased risk of mortality (Kroenke et al. 2006). In 
our model, the presence of a caregiver was unexpectedly 
related to worse survival, probably because in an outpatient 
setting, those requiring a caregiver could have been the 
most vulnerable ones.
The calculation of Onco-MPI can be easily performed 
through an excel file in which the value of each domain 
(age, sex, BMI, ADL, IADL, ECOG PS, MMSE, number 
of severe comorbidity, cancer stage, tumor site, number 
of drugs, the presence of caregiver) is multiplied by the 
coefficient which is the weight for Onco-MPI (reported in 
Table 3).
From a practical standpoint, we can take the example 
of an 80-year-old woman with stage III colorectal cancer, 
PS 1, ADL 6/6, IADL 5/8, BMI 28, good cognitive status 
(MMSE ≥ 24), two severe comorbidity, five drugs, with 
caregiver present; this patient has an Onco-MPI score 
of 0.44, which means that she is in the lower Onco-MPI 
score, with an estimated risk of mortality at 1 year of 
2.1 %. The same woman, but having a bad cognitive sta-
tus (MMSE < 24) and BMI 19, has an Onco-MPI score 
of 0.54, which means that she is in the intermediate risk 
group, with an estimated one-year mortality of 17.7 %. If 
this patient had ADL 5/6, her Onco-MPI would be 0.72, 
which corresponds to higher risk of mortality at 1 year, 
estimated to be more than 80 %. While adjuvant treatment 
may be discussed in the first case and carefully evaluated in 
the second case, in the third case geriatric assessment and 
oncoMPI suggest not to consider adjuvant chemotherapy. 
It is important to notice that the patient was judged as hav-
ing a PS 1 in all cases, thus confirming that comprehensive 
geriatric assessment adds information, and in the case of 
the Onco-MPI adds prognostic information, to simple PS 
estimation (Repetto et al. 2002).
The main limitations of the present study were the pos-
sible selection of more “fit” older cancer patients and the 
lack of data of the predictive role of the Onco-MPI for 
Table 3  Estimated domains weights used to compute the onco-mul-
tidimensional prognostic index (MPI), for mortality risk prediction 




Age (years) Cont. Var. 0.04730
Sex Female  (ref) 0
Male 0.01706
BMI Cont. Var. -0.09782
ADL Cont. Var. -0.07717
IADL Cont. Var. 0.04983
ECOG Performance Status Cont. Var. 0.70607













MMSE Cont. Var. -0.06270
N°of drugs Cont. Var. -0.01218
Caregiver No  (ref) 0
Yes 0.21035
Raw onco-MPI R= ∑ (Si.Di)





Low 0 - 0.46
Medium 0.47 - 0.63






Defined using: age, sex, BMI body mass index, ADL activities of 
daily living, IADL instrumental activities of daily living, ECOG East-
ern Cooperative Oncology Group performance status, CIRS Cumula-
tive Illness Rating Scale, MMSE mini-mental state examination, num-
ber of drugs, the presence of a caregiver, cancer stage and tumor size
Cont. Var. continuous variable
* Survival C-index, along with 95 % confidence intervals (CI), and p 
value from Hosmer–Lemeshow (HL) goodness-of-fit test for calibra-
tion of the Onco-MPI score within 1 year of follow-up
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mid- and long-term mortality. The Onco-MPI has been 
built on outpatients; therefore, there is a greater likeli-
hood of the inclusion of less frail patients which may 
have skewed the results. However, it holds a very good 
discriminatory power with a C-statistic of 0.87. In fact, 
despite the lack of accepted criteria to assess the qual-
ity of prognostic indices, generally C-statistics for dis-
crimination can be considered good for ranges 0.70–0.79, 
very good for ranges 0.80–0.89, and excellent for 0.90 
or greater (Yourman et al. 2012). Beyond its prognostic 
ability, the Onco-MPI could also serve as an useful tool 
for evaluating effectiveness of an intervention in differ-
ent settings, when changes in Onco-MPI categories that 
can be obtained may reflect the outcome of the interven-
tion, as recently reported in older patients with late-life 
major depressive disorder responders and non-responders 
to antidepressant treatment (Pilotto et al. 2012a, b, c). 
Finally, the Onco-MPI in the research setting may help to 
properly classify patients enrolled in clinical trials, select-
ing more homogeneous subgroups of patients. However, 
the Onco-MPI warrants external validation, which is 
Table 4  Results from 
multivariable Cox regressions 
for mortality risk prediction, 
within 1 year of follow-up in 
older cancer patients
BMI body mass index, ADL activities of daily living, IADL instrumental activities of daily living, CIRS 
Cumulative Illness Rating Scale, MMSE mini-mental state examination, ECOG Eastern Cooperative 
Oncology Group, Cont. Var. continuous variable
Variable Category HR (95 % CI) p value
Age Cont. Var. 1.040 (0.996–1.086) 0.075
Sex Male versus female 1.018 (0.647–1.600) 0.939
BMI Cont. Var. 0.912 (0.859–0.968) 0.002
ADL Cont. Var. 0.920 (0.751–1.128) 0.423
IADL Cont. Var. 1.008 (0.870–1.167) 0.92
Comorbidity index CIRS Cont. Var. 0.914 (0.749–1.114) 0.372
MMSE <24 versus ≥24 0.971 (0.595–1.584) 0.906
Psychiatric diseases Yes versus no 0.498 (0.198–1.251) 0.138
Cancer stage IV versus I 6.689 (2.950–15.166) <0.001
III versus I 2.129 (0.854–5.306) 0.105
II versus I 3.335 (1.389–8.009) 0.007
Cancer treatment Yes versus no 0.984 (0.618–1.567) 0.945
No of drugs Cont. Var. 1.023 (0.923–1.133) 0.668
ECOG performance status ≥3 versus 0 7.747 (1.744–34.411) 0.007
2 versus 0 3.827 (1.777–8.244) <0.001
1 versus 0 3.122 (1.877–5.191) <0.001
Caregiver Yes versus no 1.193 (0.708–2.010) 0.508
15-item Geriatric Depression Scale >5 versus ≤5 0.947 (0.574–1.564) 0.833
Syndromes Yes versus no 1.050 (0.494–2.234) 0.898
Tumor site Breast versus other 0.164 (0.068–0.396) <0.001
Colorectal versus other 0.379 (0.214–0.671) <0.001
Lung versus other 1.407 (0.767–2.579) 0.270
Prostate versus other 0.209 (0.073–0.599) 0.004
Other genitourinary versus other 1.260 (0.652–2.433) 0.492
Fig. 1  Kaplan-Meier survival curves, within 1 year of follow-up, 
according to the three Onco-MPI risk score categories (low risk, 
medium risk and high risk)
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already underway, and proof of ability to predict mortality 
with longer follow-up.
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